ABIVAX
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Abivax is a clinical-stage biotechnology company that develops therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's core innovation lies in its novel approach to microRNA biology. Its lead drug candidate, obefazimod, is a first-in-class, orally administered small molecule designed to enhance the expression of miR-124, a natural regulator of the inflammatory response. Obefazimod is in late-stage clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Abivax's pipeline includes exploring obefazimod for other inflammatory indications and developing follow-on compounds from its proprietary chemical library.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ABIVAX and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-16 18:00 |
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | |
| 2025-09-16 09:59 |
Major Shareholding Notification
Franchissement de seuil
|
French | 121.4 KB | |
| 2025-09-12 17:45 |
Regulatory News Service
Abivax intègrera les indices CAC Mid 60 et SBF 120 suite à la révision annuelle…
|
French | 160.0 KB | |
| 2025-09-12 17:45 |
Regulatory News Service
Abivax integrera les indices CAC Mid 60 et SBF 120 suite a la revision annuelle…
|
French | 21.0 KB | |
| 2025-09-12 17:45 |
Regulatory News Service
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual R…
|
English | 8.6 KB | |
| 2025-09-08 22:00 |
Earnings Release
Abivax Presents First Half 2025 Financial Results
|
English | 24.2 KB | |
| 2025-09-02 10:55 |
Regulatory News Service
Franchissement de seuil
|
French | 121.8 KB | |
| 2025-08-13 18:00 |
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | |
| 2025-08-11 15:21 |
Major Shareholding Notification
Franchissement de seuil
|
French | 111.2 KB | |
| 2025-08-11 15:16 |
Major Shareholding Notification
Franchissement de seuils
|
French | 117.2 KB | |
| 2025-08-11 11:11 |
Major Shareholding Notification
Franchissement de seuil
|
French | 99.3 KB | |
| 2025-07-28 22:15 |
Share Issue/Capital Change
Abivax Announces Closing of $747.5 Million Public Offering
|
English | 15.0 KB | |
| 2025-07-25 08:00 |
Share Issue/Capital Change
Abivax Announces Full Exercise of Underwriters Option to Purchase Additional AD…
|
English | 15.2 KB | |
| 2025-07-24 07:30 |
Share Issue/Capital Change
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur …
|
French | 11.3 KB | |
| 2025-07-23 22:15 |
Prospectus
Abivax annonce le lancement dune offre au public
|
French | 43.8 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
